Comment re: continuous rather than intermittent administration of fenretinide in leukoplakia.
Formelli
Franca
F
Cavadini
Elena
E
Appierto
Valentina
V
Tiberio
Paolo
P
Grigolato
Roberto
R
Chiesa
Fausto
F
Tradati
Nicoletta
N
Persiani
Stefano
S
D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D017313:Fenretinide / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007972:Leukoplakia, Oral / Q000188:drug therapy*; D012107:Research Design; D013997:Time Factors; D016896:Treatment Outcome
D016588:Anticarcinogenic Agents; D017313:Fenretinide